The Bulletin is available as a summary and complete bulletin. It summarises the efficacy associated many methods of contraception and discusses the risks (VTE, cancers, MI and Stroke) linked to the popular treatment options.
The evidence and place in therapy of some newer options is also covered with an analysis of the evidence available for Cerazette®, Evra® and Yasmin®.
The article also provides a reminder about the recent NICE guideline regarding the use of long acting reversible contraceptives and the MHRA warnings about co-cyprindiol (Dianette®) relating to venous thromboembolism (VTE) and depression.
Action: Clinicians involved in the provision of contraceptive services will find this bulletin useful. It provides a concise summary and discussion of current issues; the summary provides a quick read containing the key messages.
|« Varenicline launch||Comparison of hypoglycaemics »|